Response to letter by Fisher et al [2]

Stroke

Volumn 38, Issue 11, 2007, Pages

  Ginsberg, Myron D ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISUFENTON SODIUM;

BRAIN ISCHEMIA; CLINICAL TRIAL; HUMAN; LETTER; NEUROPROTECTION; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

EID: 35649012715     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STROKEAHA.107.502153     Document Type: Letter

References (15)

1. Hess DC. NXY-059: a hopeful sign in the treatment of stroke. Stroke. 2006;37:2649-2650.
2. Fisher M. NXY-059 for acute ischemic stroke: the promise of neuroprotection is finally realized? Stroke. 2006;37:2651-2652.
3. Hachinski V. Clarification. Stroke. 2006;37:2648.
4. Fisher M, Hess DC, Lees KR. Issues pertaining to the critiques of the SAINT-I trial. Stroke. 2007;38:e126-e127.
5. American College Dictionary. New York, NY: Random House; 1956.
6. Ginsberg MD. Life after Cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era. Stroke. 2007;38:1967-1972.
7. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
8. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562-571.
9. Koziol JA. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:2075-2076.
10. Serebruany V. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:2075-2076.
11. Koziol JA, Feng AC. On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke. Stroke. 2006;37:2644-2647.
12. Serebruany VL. Hypokalemia, cardiac failure, and reporting NXY-059 safety for acute stroke. J Cardiovasc Pharmacol Ther. 2006;11:229-231.
13. Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol. 2007;205:20-25.
14. Feuerstein GZ, Zaleska MM, Krams M, Wang X, Day M, Rutkowski JL, Finklestein SP, Pangalos MN, Poole M, Stiles GL, Ruffolo RR, Walsh FL. Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab. 2007; June 20:1-3. Epub ahead of print.
15. Garber K. Stroke treatment-light at the end of the tunnel? Nat Biotechnol. 2007;25:838-840.